Download Free Sample Report

Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms.
Due to the COVID-19 pandemic, the global Tetanus Toxoid Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Tetanus Toxoid Vaccine market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Tetanus Toxoid Vaccine landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare.
This report focuses on Tetanus Toxoid Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Tetanus Toxoid Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Tetanus Toxoid Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

• Monovalent Tetanus Toxoid (TT)
• Diphtheria
• Tetanus
• Pertussis (DTaP)
• Diphtheria and Tetanus (DT)

Segment by Application

• Hospitals And Clinics
• Government Organizations
• Research
• Others

By Region

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Australia
• Taiwan
• Indonesia
• Thailand
• Malaysia
• Philippines
• Vietnam
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE

By Company

• GlaxoSmithKline
• Merck
• Pfizer
• Sanofi Pasteur
• AstraZeneca
• Bharat Biotech
• Shenzhen Kangtai Biological Products
• Bausch Health
• Emergent Biosolutions
• Astellas Pharma
• Panacea Biotec